Insulin-like Growth Factor Receptor Inhibition as Maintenance Therapy for Metastatic Ewing Sarcoma.
Despite the advances in oncology, the survival of children with Ewing Sarcoma metastatic at diagnosis continues to be 27% 3-year event-free survival and 34% 3-year overall survival. In other words, 7 of 10 children die within 3 years of their initial diagnosis despite intense chemotherapy, local treatment (radiation/surgery), and/or high dose busulfan-melphalan and autologous stem-cell transplantation. A chief contributor to this morbidity and mortality is the difficulty eradicating the tumor using present therapeutic modalities. Despite the extensive surgery, intensive chemotherapy and radiation, those left with a significant bulk of residual tumor relapse within a year of completing treatment. This case report suggests that in children left with a significant tumor burden after completing chemotherapy, a prolonged period of stability can be achieved with biological agents targeting the underlying molecular drivers. In this particular case we used figitumumab, an antibody targeting the insulin-like growth factor type 1 receptor pathway, a documented target in Ewing Sarcoma. Although not curative, these agents provide a better quality of life.
Department of Pediatrics, Floating Hospital for Children at Tufts Medical Center, Boston, MA.
Hannah
H
Fassel
Donald
D
Tracy
Katie
K
Louer
Giannoula Lakka
GL
Klement
D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D017451:Receptors, Somatomedin / Q000037:antagonists & inhibitors*; D012512:Sarcoma, Ewing / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary
D000911:Antibodies, Monoclonal; D017451:Receptors, Somatomedin; C525021:figitumumab